ArticleNature cancer2023
Considering molecular alterations as pan-cancer tissue-agnostic targets.
Article in Nature cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Mucin-1: a promising pan-cancer therapeutic target.NPJ precision oncology · 2025Review
- Tumour-agnostic kinase inhibitors.Nature reviews. Drug discovery · 2025Review
- Comparing functional and genomic-based precision medicine in blood cancer patients.HemaSphere · 2025Article
- If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide.Med (New York, N.Y.) · 2025Review
- Genomics of uterine malignancies and the potential of precision medicine.Therapeutic advances in medical oncology · 2025Review
- If it's a target, it's a pan-cancer target: Tissue is not the issue.Cancer treatment reviews · 2024Review
- Article
- Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors.Therapeutic advances in medical oncology · 2024Article
- Novel clinical trial designs emerging from the molecular reclassification of cancer.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.